Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Apr 9, 2020 23:35:42 GMT -5
It's likely that there is no money involved given the finding status of Immix. Whoops, that should have been "funding status of Immix." I'm pretty sure they are applying for COVID-19 Federal Grants for R&D.
|
|
|
Post by Chris-C on Apr 10, 2020 13:07:13 GMT -5
It would be marvelous if promising anti-viral candidates would consider partnering to deliver directly to the tissues of the lung, and I thought of this several times during the past few weeks. Clearly I'm not the only way underwater investor with these dreams here.
I'm not a pulmonary physiologist, virologist, immunologist, or pharmacologist, so I suspect there are a host of potential safety issues related to delivering such drugs through inhalation therapy. That said, even a mention that MNKD was collaborating with an established partner on this would be a positive development, to say the least.
Let's keep our recently washed fingers crossed, not for our portfolios on life support, but for humans (those numbers represent spouses, parents, grandparents, siblings, friends, colleagues and neighbors whose systems got overwhelmed with these deadly strands of RNA) whose only misfortunate act was being social at the wrong place and time. God bless them all, and their families.
Be safe. Godspeed.
GLTAL
Chris
|
|
|
Post by goyocafe on Apr 15, 2020 6:20:43 GMT -5
ARDS treatment landscape
That’s a lot of research. ARDS surely looks like a high focus area.Click on the link “Open table in new window” at the top of the list to get a better view.
|
|
|
Post by itellthefuture777 on May 19, 2020 22:32:33 GMT -5
www.purdue.edu/newsroom/releases/2020/Q2/purdue-developed-nanomaterial-significantly-enhances-potential-covid-19-therapeutic.html
Yao’s research tested OHPP-developed niclosamide against the drug alone and the drug treated with other commercially available solubilizers. The OHPP formulation was over 5,000 times more soluble than niclosamide alone and 50 times more powerful than the leading commercial solubilizers.
Yao co-founded a startup company, Phytoption LLC, in the Purdue Research Park. The company is now looking for strategic partners to advance OHPP-enabled niclosamide formulations and join the global efforts against COVID-19.
“We are fortunate that we have a platform technology ready for the formulation of niclosamide, which is based on years of time and effort, along with the support from the National Science Foundation, and many organizations in Indiana,” Phytoption CEO Joanne Zhang said. “The COVID-19 pandemic presents an urgent need to assemble a strategic team and bring the technology to the market. If you are interested, let’s collaborate and fight this pandemic together.”
|
|
|
Post by itellthefuture777 on May 19, 2020 22:43:23 GMT -5
|
|
|
Post by itellthefuture777 on May 19, 2020 22:44:09 GMT -5
|
|